Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Kushi Kullar who wrote (28272)	2/18/1999 11:17:00 PM
From: Machaon	Read Replies (2) \| Respond to of 32384

Well, there could be a good side to all of this. If the LLY/LGND alliances are bypassing both Targretin and the second generation agonists LGD1268 and LGD1324 AND Ligand is boasting about their alliance results with Lilly, then they must have come up with some powerful pre-clinical diabetes test results on new agonist compounds, probably as a result of improvements to the old compounds. That could mean that there are a couple dozen more naked mice running around the labs with their diabetes cured and with only minor side effects, like a craving for double cheese on their meece pizza? Hmmmmm!? I might just pick up some more LGND shares in the near future if we drop down into single digits. Most of the Ligand story is still intact.